11:46 AM EDT, 05/07/2024 (MT Newswires) -- Supernus Pharmaceuticals ( SUPN ) and M8 Pharmaceuticals have signed a licensing agreement to seek regulatory clearance and sell Qelbree under M8's trademark in Latin America, M8 said Tuesday.

Qelbree is approved in the US to treat attention deficit hyperactivity disorder, or ADHD in adults and children aged six and older, M8 said.

Financial details weren't provided.

Supernus shares were rising over 1% in recent trading.

Price: 30.83, Change: +0.40, Percent Change: +1.33